These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 37744290)
21. Comparing Post-Operative Outcomes of Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: Neoadjuvant Therapy Versus Surgery First Approach. Hyman DW; Almerey T; Mujkanovic A; Hammons I; Tice M; Stauffer JA Am Surg; 2022 Aug; 88(8):1868-1874. PubMed ID: 35465681 [TBL] [Abstract][Full Text] [Related]
22. Update on the management of pancreatic cancer: surgery is not enough. Ansari D; Gustafsson A; Andersson R World J Gastroenterol; 2015 Mar; 21(11):3157-65. PubMed ID: 25805920 [TBL] [Abstract][Full Text] [Related]
23. Perspectives in the treatment of pancreatic adenocarcinoma. Cid-Arregui A; Juarez V World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356 [TBL] [Abstract][Full Text] [Related]
24. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma. Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998 [TBL] [Abstract][Full Text] [Related]
25. Defining the Optimal Duration of Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma: Time for a Personalized Approach? Puleo A; Malla M; Boone BA Pancreas; 2022 Oct; 51(9):1083-1091. PubMed ID: 37078929 [TBL] [Abstract][Full Text] [Related]
26. Association Between Pancreatic Fistula and Long-term Survival in the Era of Neoadjuvant Chemotherapy. Hank T; Sandini M; Ferrone CR; Rodrigues C; Weniger M; Qadan M; Warshaw AL; Lillemoe KD; Fernández-Del Castillo C JAMA Surg; 2019 Oct; 154(10):943-951. PubMed ID: 31411659 [TBL] [Abstract][Full Text] [Related]
27. Prediction of margin-negative resection of pancreatic ductal adenocarcinoma following neoadjuvant therapy: Diagnostic performance of NCCN criteria for resection vs CT-determined resectability. Jang JK; Choi SJ; Byun JH; Kim JH; Lee SS; Kim HJ; Yoo C; Kim KP; Hong SM; Seo DW; Hwang DW; Kim SC J Hepatobiliary Pancreat Sci; 2022 Sep; 29(9):1025-1034. PubMed ID: 35658103 [TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant therapy alters the collagen architecture of pancreatic cancer tissue via Ephrin-A5. Nakajima K; Ino Y; Naito C; Nara S; Shimasaki M; Ishimoto U; Iwasaki T; Doi N; Esaki M; Kishi Y; Shimada K; Hiraoka N Br J Cancer; 2022 Mar; 126(4):628-639. PubMed ID: 34824448 [TBL] [Abstract][Full Text] [Related]
29. Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy. Wijetunga AR; Chua TC; Nahm CB; Pavlakis N; Clarke S; Chan DL; Diakos C; Maloney S; Ashrafi-Zadeh A; Kneebone A; Hruby G; Jamieson NB; Gill A; Mittal A; Samra JS Eur J Surg Oncol; 2021 Oct; 47(10):2543-2550. PubMed ID: 33952409 [TBL] [Abstract][Full Text] [Related]
30. Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan. Ei S; Takahashi S; Ogasawara T; Mashiko T; Masuoka Y; Nakagohri T Gut Liver; 2023 Sep; 17(5):698-710. PubMed ID: 36843421 [TBL] [Abstract][Full Text] [Related]
31. Pancreatic Cancer: A Review. Park W; Chawla A; O'Reilly EM JAMA; 2021 Sep; 326(9):851-862. PubMed ID: 34547082 [TBL] [Abstract][Full Text] [Related]
33. Survival equivalence in patients treated for borderline resectable and unresectable locally advanced pancreatic ductal adenocarcinoma: a systematic review and network meta-analysis. Lindemann J; du Toit L; Kotze U; Bernon M; Krige J; Jonas E HPB (Oxford); 2021 Feb; 23(2):173-186. PubMed ID: 33268268 [TBL] [Abstract][Full Text] [Related]